vecuronium
Trade name: norcuron
Approved
Apr 30, 1984
Vecuronium is a neuromuscular blocking agent. Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia. Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. Vecuronium is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. — NCATS
Clinical trial activity
13 trials · 29 clinical orgs · 14 marketing orgs
Earliest trial started Feb 1, 2003 (NCT00970762)
Timeline
1980s
1990s
- Aug 31, 1995
Watson Pharmaceuticals — Marketing Organization
- Aug 23, 1999
West-Ward Pharmaceutical — Marketing Organization
- Aug 25, 1999
Teva — Marketing Organization
- Aug 25, 1999
Eu Yan Sang — Marketing Organization
- Aug 25, 1999
Meitheal — Marketing Organization
- Oct 21, 1999
Hospira — Marketing Organization
2000s
- Jan 1, 2003
Earliest Phase 3 Sponsor(trial)
- Dec 29, 2008
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Jun 17, 2009
Sun Pharmaceuticals — Marketing Organization
2010s
- May 11, 2010
Mylan — Marketing Organization
- May 26, 2016
Gland Pharma Ltd — Marketing Organization
- Dec 20, 2018
Aurobindo Pharma — Marketing Organization
- Dec 20, 2018
Eugia Pharma — Marketing Organization
- Jul 30, 2019
Hikma — Marketing Organization
Indications
Approved for
Studied for
- Analgesics, Opioid · Phase 4
- Anesthesia · Phase 4
- Arthritis · Phase 4
- Arthropathy, Neurogenic · Phase 4
- Brain Injuries · Phase 4
- Cognition Disorders · Phase 4
- Coronary Disease · Phase 4
- Gallstones · Phase 4
- Laparoscopy · Phase 4
- Neuromuscular Blockade · Phase 4
- Osteoarthritis · Phase 4
- Postoperative Complications · Phase 4
- Rotator Cuff Injuries · Phase 4
- Vascular Diseases · Phase 4
Mechanism of action
Approval history
- approvedApr 30, 1984
Chemistry & pharmacology
SMILES
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1- Mol. weight
- 557.84 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201219 ↗
- WikipediaVecuronium bromide ↗
- NCATS5438723848 ↗
- ChEMBLCHEMBL1200629 ↗
Also known as
- musculax
- musculax
- norcuron
- norcuron
- norcuron
- org nc 45
- org nc 45
- org nc 45
- org-nc 45
- org-nc 45
- vecuronium
- vecuronium
- vecuronium
- vecuronium
- vecuronium
- vecuronium
- vecuronium
- vecuronium bromide
- vecuronium bromide
- vecuronium bromide
- vecuronium bromide
- vecuronium citrate
- vecuronium hcl
- vecuronium hydrobromide
- vecuronium hydrobromide
- vecuronium hydrobromide
- vecuronium hydrobromide
- vecuronium hydrobromide
- vecuronium hydrobromide
- vecuronium hydrochloride
- vecuronium maleate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03346070 | Phase 4 | Jan 1, 2018 | Merck |
| NCT03371953 | Phase 4 | Dec 20, 2017 | Sir Ganga Ram Hospital |
| NCT03219294 | Phase 4 | May 1, 2017 | Spectrum Medical Group, Tufts University |
| NCT03540030 | Phase 4 | Aug 31, 2016 | OrthoCarolina Research Institute |
| NCT02727712 | Phase 4 | Apr 1, 2016 | Central South University |
| NCT02327923 | Phase 4 | Oct 1, 2014 | B.P. Koirala Institute of Health Sciences |
| NCT02237443 | Phase 4 | Aug 1, 2014 | University of Washington |
| NCT02123355 | Phase 4 | Aug 1, 2014 | Chinese Medical Association, Shaanxi Provincial People's Hospital |
| NCT02134093 | Phase 4 | Jul 1, 2014 | People's Liberation Army of China |
| NCT02619578 | N/A | Nov 1, 2013 | Guizhou Medical University |
| NCT01690338 | Phase 4 | Oct 1, 2012 | Central South University, China Medical University, Eastern Hepatobiliary Surgery Hospital, Fudan University, Guangzhou Medical University, Hebei University, Huazhong University of Science and Technology, Jiao Tong University, Peking University, People's Liberation Army of China, Sichuan University, Southern Medical University, Sun Yat-Sen University, Tianjin Medical University, Tsinghua University, Xinjiang Medical University, Zhejiang University, Zhengzhou University |
| NCT01690364 | N/A | Jul 31, 2012 | Sungkyunkwan University |
| NCT00970762 | Phase 3 | Feb 1, 2003 | Merck |
Organizations
Research & Development (29)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Central South University | Academic/Hospital | 2 | 1 | 1 | 2012 |
| Merck | For profit | 2 | 2 | 2 | 2003 |
| People's Liberation Army of China | Government | 2 | 1 | 1 | 2012 |
| B.P. Koirala Institute of Health Sciences | Academic/Hospital | 1 | 1 | 1 | 2014 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Chinese Medical Association | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Eastern Hepatobiliary Surgery Hospital | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Guangzhou Medical University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Guizhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Hebei University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| OrthoCarolina Research Institute | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Shaanxi Provincial People's Hospital | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Sir Ganga Ram Hospital | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Spectrum Medical Group | Academic/Hospital | 1 | 0 | 1 | 2017 |
Marketing (19)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Aurobindo Pharma | For profit | MKTG | Dec 20, 2018 |
| Eu Yan Sang | For profit | MKTG | Aug 25, 1999 |
| Eugia Pharma | For profit | MKTG | Dec 20, 2018 |
| Gland Pharma Ltd | For profit | MKTG | May 26, 2016 |
| Gland Pharma Ltd | For profit | MKTG | May 26, 2016 |
| Hikma | For profit | MKTG | Jul 30, 2019 |
| Hikma | For profit | SYN | Aug 23, 1999 |
| Hospira | For profit | MKTG | Oct 21, 1999 |
| Meitheal | For profit | MKTG | Aug 25, 1999 |
| Mylan | For profit | MKTG | May 11, 2010 |
| Organon | For profit | NDA2 | Apr 30, 1984 |
| Organon | For profit | NDA | Apr 30, 1984 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Dec 29, 2008 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Dec 29, 2008 |
| Sun Pharmaceuticals | For profit | MKTG | Jun 17, 2009 |
| Sun Pharmaceuticals | For profit | SYN | Jun 17, 2009 |
| Teva | For profit | MKTG | Aug 25, 1999 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 31, 1995 |
| West-Ward Pharmaceutical | For profit | MKTG | Aug 23, 1999 |